PDF herunterladen
Semin Thromb Hemost 2021; 47(01): 084-089
DOI: 10.1055/s-0040-1718870
Review Article

ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers

Massimo Franchini
1   Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy
,
Antonio Coppola
2   Regional Reference Center for Inherited Bleeding Disorders, University Hospital, Parma, Italy
,
Cristina Santoro
3   Department of Hematology, Policlinico Umberto I University Hospital, Rome, Italy
,
Raimondo De Cristofaro
4   Hemorrhagic and Thrombotic Diseases Service, Area of Hematology, Fondazione Policlinico Universitario “A. Gemelli,” IRCCS, Rome, Italy
,
Giovanni Barillari
5   Center for Hemorrhagic and Thrombotic Disorders, General and University Hospital, Udine, Italy
,
Paola Giordano
6   Pediatric Unit “B. Trambusti,” Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro,” Bari, Italy
,
Paolo Gresele
7   Section of Internal and Cardiovascular Medicine, Department of Medicine, University of Perugia, Perugia, Italy
,
Giuseppe Lassandro
6   Pediatric Unit “B. Trambusti,” Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro,” Bari, Italy
,
Mariasanta Napolitano
8   Hematology Unit, Department of Health Promotion, Mother and Child Care, Reference Regional Center for Thrombosis and Haemostasis, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy
,
Giuseppe Lucchini
1   Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy
,
Matteo Luciani
9   Oncohematology Department, Pediatric Hospital Bambino Gesù, Rome, Italy
,
Antonietta Ferretti
3   Department of Hematology, Policlinico Umberto I University Hospital, Rome, Italy
,
Erminia Baldacci
3   Department of Hematology, Policlinico Umberto I University Hospital, Rome, Italy
,
Federica Riccardi
2   Regional Reference Center for Inherited Bleeding Disorders, University Hospital, Parma, Italy
,
Rita Carlotta Santoro
10   Center for Hemorrhagic and Thrombotic Disorders, “Pugliese-Ciaccio” Hospital, Catanzaro, Italy
,
Samantha Pasca
11   Hemophilia Center, University Hospital of Padua, Padua, Italy
,
Ezio Zanon
11   Hemophilia Center, University Hospital of Padua, Padua, Italy
,
Annarita Tagliaferri
2   Regional Reference Center for Inherited Bleeding Disorders, University Hospital, Parma, Italy
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Considering the profound influence exerted by the ABO blood group system on hemostasis, mainly through the von Willebrand factor and factor VIII (FVIII) complex, we have conducted a study evaluating the possible role of blood type on the risk of inhibitor development in hemophilia A. A total of 287 consecutive Caucasian patients with severe hemophilia A (202 without FVIII inhibitors and 85 with FVIII inhibitors) followed at seven Italian Hemophilia Treatment Centers belonging to the Italian Association of Hemophilia Centers (AICE) were included in the study. A higher prevalence of O blood group was detected in patients without inhibitors as compared in inhibitor patients (55 vs. 30.6%; p < 0.001). Among the other variables analyzed (age, F8 mutation, type and intensity of treatment and treatment regimen), F8 mutation class (high-risk vs. low-risk), and treatment regimen (on-demand vs. prophylaxis) were significantly correlated with inhibitor development. However, on a multivariate analysis, only the effects of F8 mutation and ABO blood type were independent of other covariates, being that non-O blood type is associated with a 2.89-fold increased risk of inhibitor development. In conclusion, our study supports the protective effect of O blood type on inhibitor risk in severely affected hemophilia A patients.

Keywords

ABO blood group - hemophilia - inhibitors - risk factors

Authors' Contributions

M.F. designed the study and coordinated its implementation in the network of AICE centers and performed data collection, analysis, and interpretation, together with A.C. and A.T. C.S., R.D.C., G.B, P.G., P.Gr., G.L., M.N., G.Lu., M.L., A.F., R.C.S., S.P., and E.Z. enrolled patients and collected their data. F.R. contributed to the analysis of F8 gene mutations. M.F. and A.C. wrote the first draft of the manuscript. All the coauthors revised the manuscript and approved the final version.




Publikationsverlauf

Artikel online veröffentlicht:
01. Februar 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9 (04) 418-435
    CrossrefPubMedGoogle Scholar
  • 2 Coppola A, Santoro C, Tagliaferri A, Franchini M, DI Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia 2010; 16 (Suppl. 01) 13-19
    CrossrefPubMedGoogle Scholar
  • 3 Miller CH, Benson J, Ellingsen D. et al; Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia 2012; 18 (03) 375-382
    CrossrefPubMedGoogle Scholar
  • 4 Gouw SC, van den Berg HM, Oldenburg J. et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119 (12) 2922-2934
    CrossrefPubMedGoogle Scholar
  • 5 Iorio A, Halimeh S, Holzhauer S. et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8 (06) 1256-1265
    CrossrefPubMedGoogle Scholar
  • 6 Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol 2012; 81 (01) 82-93
    CrossrefPubMedGoogle Scholar
  • 7 Franchini M, Coppola A, Rocino A. et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update. Semin Thromb Hemost 2013; 39: 752-766
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 8 Peyvandi F, Mannucci PM, Garagiola I. et al. A randomized trial of Factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374 (21) 2054-2064
    CrossrefPubMedGoogle Scholar
  • 9 Gouw SC, Fijnvandraat K. Identifying nongenetic risk factors for inhibitor development in severe hemophilia a. Semin Thromb Hemost 2013; 39 (07) 740-751
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 10 Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 2015; 125 (13) 2019-2028
    CrossrefPubMedGoogle Scholar
  • 11 Dasgupta S, Repessé Y, Bayry J. et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109 (02) 610-612
    CrossrefPubMedGoogle Scholar
  • 12 Oldenburg J, Lacroix-Desmazes S, Lillicrap D. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity. Haematologica 2015; 100 (02) 149-156
    CrossrefPubMedGoogle Scholar
  • 13 Liumbruno GM, Franchini M. Beyond immunohaematology: the role of the ABO blood group in human diseases. Blood Transfus 2013; 11 (04) 491-499
    PubMedGoogle Scholar
  • 14 Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. Transfusion 2006; 46 (10) 1836-1844
    CrossrefPubMedGoogle Scholar
  • 15 Gallinaro L, Cattini MG, Sztukowska M. et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111 (07) 3540-3545
    CrossrefPubMedGoogle Scholar
  • 16 Franchini M, Crestani S, Frattini F, Sissa C, Bonfanti C. ABO blood group and von Willebrand factor: biological implications. Clin Chem Lab Med 2014; 52 (09) 1273-1276
    CrossrefPubMedGoogle Scholar
  • 17 Vlot AJ, Mauser-Bunschoten EP, Zarkova AG. et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000; 83 (01) 65-69
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 18 Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91 (02) 474-476
    CrossrefPubMedGoogle Scholar
  • 19 Fischer K, Pendu R, van Schooten CJ. et al. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS One 2009; 4 (08) e6745
    CrossrefPubMedGoogle Scholar
  • 20 Franchini M, Mengoli C, Marano G, Pupella S, Mannucci PM, Liumbruno GM. The importance of ABO blood group in pharmacokinetic studies in haemophilia A. Haemophilia 2018; 24 (03) e122-e123
    CrossrefPubMedGoogle Scholar
  • 21 Franchini M, Coppola A, Mengoli C. et al; ad hoc Study Group. ad hoc Study Group. Blood group O protects against inhibitor development in severe hemophilia A patients. Semin Thromb Hemost 2017; 43 (01) 69-74
    PubMedGoogle Scholar
  • 22 Van Den Berg M, Oldenburg J, Carcao M. et al. Does blood group O influence inhibitor development? Data frome the PEDNET registry [abstract]. Haemophilia 2018; 42 (Suppl. 01) 105
    PubMedGoogle Scholar
  • 23 Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12 (Suppl. 03) 52-60
    CrossrefPubMedGoogle Scholar
  • 24 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
    CrossrefPubMedGoogle Scholar
  • 25 Franchini M, Lippi G. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?. Thromb Res 2016; 148: 96-100
    CrossrefPubMedGoogle Scholar
  • 26 Gill JC, Stephany K, Newton-Nash D, Foster PA. Apparent IgG anti-factor VIII antibodies in normal individuals are specific for AB0 blood group substances [abstract]. Thromb Haemost 1995; 86: 611
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 27 Bachelet D, Albert T, Mbogning C. et al; ABIRISK consortium. Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A. PLoS One 2019; 14 (06) e0218258
    CrossrefPubMedGoogle Scholar
  • 28 Mannucci PM, Mancuso ME, Franchini M. Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A. J Thromb Haemost 2016; 14 (07) 1330-1336
    CrossrefPubMedGoogle Scholar